Our People

Board

Dr Michael McAuliffe

Dr Michael McAuliffe

Founding Director & Chair: Scientific & Clinical Advisory Panel

Dr Michael McAuliffe is a practising Orthopaedic surgeon and father of a daughter with Type 1 diabetes. In his clinical practice, Michael specialises in surgery of the lower limb. He has invented and commercialised novel technologies to improve therapeutic outcomes for his own patients and was the inspiration behind the inter-disciplinary concepts that Captixbio’s technologies are based on. Michael is a member of the Australian Orthopaedic Association, The Australian Knee Society, The American Hip and Knee Association, a PhD candidate at Queensland University of Technology and a senior lecturer at the University of Queensland. He is also an active participant at both clinical advisory and event level in the “Tour de Cure”.

Michael graduated MBBS from University of Queensland, subsequently completing his orthopaedic training and is now a Fellow of the Royal Australasian College of Surgeons and a Fellow of the Australian Orthopaedic Association.

Glenn Cross

Glenn Cross

Non-Executive Director

Glenn Cross is an experienced Senior Life Sciences Executive who has spent his life working in life sciences progressing from the lab bench to senior executive positions. He has over 40 years’ experience in this sector and has held senior executive roles in both multinational and Australian companies.

Glenn’s expertise covers general management, sales, marketing, finance, distribution, and manufacturing in the life sciences market. He also has experience in human resources, product development and manufacturing.

In recent years Glenn has been involved in capital markets and general investment activities in North America, Asia, and Australia. Glenn was the Chief Operating Officer and CEO of AusBiotech for over 13 years.

Helen Wray

Helen Wray

Non-Executive Director

Following almost four years in an executive role with Captixbio, Helen transitioned to the Board in August 2021.

Helen’s career in the life sciences and medical technologies industry, has spanned over 25 years, working predominantly in the commercialisation of regenerative medicine and implantable technologies. She has held leadership and executive roles for a diverse range of multi-national and Australian life science companies.

Helen has significant experience in managing technology transfer and scale up, as well as product approvals and commercial launches for public and private companies. For more than 10 years, she held an executive director role at Capra Commercialisation Partners consulting to start-up companies as well as mentoring for CSIRO through their ON Connect Program.

Helen has a Bachelor of Science (Hons Path) and Master of Business Administration (Adv), from the University of Western Australia, a Master of IP Law from the University of Melbourne and is also a Graduate of the Australian Institute of Company Directors.

Executive

Duncan Thomson

Duncan Thomson

CEO

Duncan Thomson is CEO of Captixbio, having been appointed in August 2021. Duncan has more than 25 years’ experience in life sciences; a truly cross disciplinary professional, Duncan has worked in clinical, sales and business roles in the development and promotion of both animal and human health technologies.

Originally graduating as a veterinarian, he progressed from seeing patients to senior management positions in Europe, North America and Australia in both big pharma and leading edge biotech.

Duncan has substantial experience in the commercialisation of new technologies including managing animal trials, successful regulatory approvals, product launches, licensing and alliances, sales and marketing.

For the last 10 years, Duncan has worked in biotech in Australia holding successful roles at Regeneus, and consulting including an advisory role at the Australian Regenerative Medicine Institute (ARMI).

Duncan has a Bachelor of Veterinary Science, from University of Sydney, and a Masters of Business Administration from Cranfield University in the UK.

Dr Mille Kolind

Dr Mille Kolind

R&D Projects Director

Dr Mille Kolind, Captixbio’s R&D Projects Director joined Captixbio in July 2019 and works closely with Captixbio’s collaborators to build, manage and progress its critical research and pre-clinical programs. Mille’s career has spanned various positions ranging from basic scientific research in cells and animal models, to method development and program delivery in start-up biotech and large pharmaceutical companies.

Mille is experienced in all stages of product development and has extensive skills in project management, technical writing, method development and validation and international technology transfers to CDMO/CMOs for both biologics and cell therapy products.

Mille has a Master of Science in Engineering, from the Technical University of Denmark and a Ph.D. in Cell Biology from the University of Copenhagen.

Scientific & Clinical Advisory Panel

Dr Thomas Loudovaris

Dr Thomas Loudovaris

Dr Thomas Loudovaris is a founding member of Captixbio’s Scientific Advisory Panel and is the Islet Transplant Program Manager in the Tom Mandel Islet Transplant Program at St Vincent’s Institute (SVI) in Melbourne, Australia. His interest in delivering protected cell therapies through encapsulation extends over a career of more than 30 years, which commenced during his post-doctoral studies at the Walter & Eliza Hall Institute and continued as a scientist and then senior manager in the Cell and Gene Therapy Unit at Baxter Healthcare, USA.

In 1999, Dr Loudovaris became a co-founder of a cell encapsulation company, TheraCyte Inc., in California. He returned to Australia in 2005 to become Islet’s Program Manager at SVI where he has taken the human pancreatic islet isolation process from a laboratory research procedure to a GMP compliant process, producing islets for human transplantation.

In addition to his role in the human islet program, he has a continued interest in research and involvement in cell transplantation and encapsulation and continues to collaborate on related projects in Australia and the USA.

Professor Ming Hao Zheng

Professor Ming Hao Zheng

Professor Minghao Zheng is a founding member of Captixbio’s Scientific Advisory Panel, and a global leader in the field of regenerative medicine.

He is Winthrop Professor of Orthopaedic Research at the University of Western Australia, heads the Bone-Brain Axis research division at the Perron Institute for Translational and Neurological Science, and is part of numerous national and international collaborative research programs. He is fellow of the Royal College of Pathologists, UK, the Royal College of Pathologists of Australasia, and the Royal Society of Medicine, and serves on the editorial boards of a number of Orthopaedics, Stem Cell and Pathology journals.

Professor Zheng is an expert in the field of regenerative medicine, in particular the translation of novel science into clinical practice, including the regeneration of tendon and cartilage using a patient’s own stem cells. He is an inventor of Matrix-induced Autologous Implantation (MACI) for cartilage repair, and co-founder of Orthocell Limited, pioneering the development of their CelGro™ collagen scaffold which has gained FDA, TGA and CE Mark approval for dental applications.

Professor Zheng is dedicated to the translation of innovative regenerative medicine technologies into optimised outcomes for cell therapies in clinical practice.

Brad Sheehan

Brad Sheehan

Brad Sheehan is one of Australia’s leading advisors in the clinical development and regulation of novel implantable technologies and regenerative medicine products. Currently the General Manager of Avania’s Asia-Pacific operations, Brad has held multiple Regulatory and Clinical executive roles in industry and the CRO service sector since 2000.

Brad is passionate about the effective and ethical translation of new and emerging technologies into clinical practice and provides advice to Captixbio on the development of a robust evidence base to support the scientific development and progression of our technologies into patients. Brad serves on an Australian based ethics committee and has held accreditation as a Clinical Research Associate with the Association of Clinical Research Professionals.

Brad holds a Bachelors degree in Nursing, a Graduate Certificate in Critical Care, a Post Graduate Diploma in Management and is a Graduate of the Australian Institute of Company Directors.

Professor Martina Stenzel

Professor Martina Stenzel

Professor Martina Stenzel’s career spans over 20 years, with a focus on polymer science and in-depth analysis to understand material properties.

Having taken a role as lecturer in Chemical Engineering at UNSW in 2002, Martina joined the organisation’s School of Chemistry in 2014, where she established a research program on polymeric nano and biomaterials. She is now Fellow of the Australian Academy of Science, Fellow of the Royal Society of New South Wales and ARC Laureate Fellow, and she is also Scientific editor of RSC journal Materials Horizons.

Martina is interested in the design of new polymeric materials for biomedical applications, in particular nanoparticles for the delivery of drug or the preparation of new polymer scaffolds to optimise the interaction between cells and the materials.

Martina has a degree in chemistry from the University of Bayreuth, Germany, and completed her PhD at the Institute of Applied Macromolecular Chemistry, University of Stuttgart, Germany.